Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study

Siddhartha Sood¹, Alexander Rimke², Brian D Rankin³, Abrahim Abduelmula⁴, Jorge R Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit¹, Fernejoy Leung⁵, Alim R Devani^{2

5

6}, Ronald Vender^{7

8}, Jensen Yeung^#^{4

6

9

10}, Vimal H Prajapati^#^{11

12

13

12

14

15}

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, AB, T2J 7E1, Canada.
³ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ Skin Health and Wellness Centre, Calgary, AB, Canada.
⁶ Probity Medical Research, Waterloo, ON, Canada.
⁷ Division of Dermatology, McMaster University, Hamilton, ON, Canada.
⁸ Dermatrials Research Inc. and Venderm Consulting, Hamilton, ON, Canada.
⁹ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.
¹⁰ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
¹¹ Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, AB, T2J 7E1, Canada. vimal@dermatologyresearch.ca.
¹² Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹³ Skin Health and Wellness Centre, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹⁴ Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹⁵ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.

^# Contributed equally.

PMID: 39900871
DOI: 10.1007/s40257-025-00922-2

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study

Siddhartha Sood et al. Am J Clin Dermatol. 2025 Mar.

. 2025 Mar;26(2):301-304.

doi: 10.1007/s40257-025-00922-2. Epub 2025 Feb 3.

Authors

Affiliations

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, AB, T2J 7E1, Canada.
³ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ Skin Health and Wellness Centre, Calgary, AB, Canada.
⁶ Probity Medical Research, Waterloo, ON, Canada.
⁷ Division of Dermatology, McMaster University, Hamilton, ON, Canada.
⁸ Dermatrials Research Inc. and Venderm Consulting, Hamilton, ON, Canada.
⁹ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.
¹⁰ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
¹¹ Dermatology Research Institute, Suite 310, 8500 Blackfoot Trail S.E., Calgary, AB, T2J 7E1, Canada. vimal@dermatologyresearch.ca.
¹² Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹³ Skin Health and Wellness Centre, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹⁴ Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.
¹⁵ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada. vimal@dermatologyresearch.ca.

^# Contributed equally.

PMID: 39900871
DOI: 10.1007/s40257-025-00922-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: None. Conflict of interest: Mr. Sood, Mr. Rimke, Dr. Rankin, Dr. Abduelmula, Dr. Georgakopoulos, Dr. Maliyar, and Mr. Bagit have no relevant disclosures. Ms. Fernejoy Leung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Arcutis, Bausch Health, BioScript Solutions, Incyte, Janssen, LEO Pharma, Novartis, and UCB. Dr. Alim R. Devani has been an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Medexus, Nimbus Lakshmi, Novartis, Pediapharm, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, UCB, and Valeant. Dr. Ronald Vender has been an advisor, consultant, speaker, and/or investigator for AbbVie, Actelion, Amgen, Aralez, Arcutis, Astellas, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Centocor, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, LEO Pharma, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. Dr. Jensen Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Anacor, Arcutis, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Dr. Vimal H. Prajapati has been an advisor, consultant, and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health/Valeant, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Cipher, Concert, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for AbbVie, AnaptysBio, Arcutis, Arena, Asana, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, Regeneron, RAPT Therapeutics, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, and UCB; received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Ethics approval: Internal review board (IRB) approval was obtained by the research ethics boards at each respective academic institution from which data were collected (Sunnybrook Health Sciences Centre [205-2018]; Women’s College Hospital [2018-0079-E]). Consent to participate: Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data. Consent for publication: Requirements for patient consent were waived for this study due to the use of anonymized and deidentified data. Availability of data and materials: Supplemental data are available electronically via Mendeley at: https://doi.org/10.17632/rkrps2sbx6.1 . Code availability: Not applicable. Author contributions: V.H.P., J.Y., R.V., and A.R.D. contributed to conceptualization and study design. S.S., A.R., B.D.R., A.A., J.R.G., K.M., A.B., and F.L. contributed to data collection. S.S. contributed to data analysis. S.S., V.H.P., J.Y., and R.V. contributed to initial drafting of the manuscript. All authors contributed to editing and approval of the final draft. Additional declarations: Jensen Yeung is an Editorial Board member of the American Journal of Clinical Dermatology. Professor Yeung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

References

1. Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101–12. https://doi.org/10.1111/jdv.18409 . - DOI - PubMed - PMC
1. Rimke A, Sood S, Rankin BD, et al. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 16-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(2):359–61. https://doi.org/10.1016/j.jaad.2024.04.027 . - DOI - PubMed
1. Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(5):936–9. https://doi.org/10.1016/j.jaad.2024.05.085 . (Epub 2024 Jun 15 PMID: 38885841). - DOI - PubMed
1. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. 2021 Mar 27;397(10280):1182]. Lancet. 2021;397(10273):475–86. https://doi.org/10.1016/S0140-6736(21)00126-4 . - DOI - PubMed
1. Loft N, Egeberg A, Rasmussen MK, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol. 2022;36(8):1284–91. https://doi.org/10.1111/jdv.18126 . - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study

Affiliations

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study

Authors

Affiliations

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources